These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39367371)

  • 21. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J; D'Haens GR; Sands BE; Ng SC; Lawendy N; Kulisek N; Guo X; Wu J; Vranic I; Panaccione R; Vermeire S
    United European Gastroenterol J; 2024 Jul; 12(6):793-801. PubMed ID: 38778549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
    Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Mar; 30(3):395-401. PubMed ID: 37209416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
    Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
    Allocca M; Catalano G; Savarino EV; Chaparro M; Levartovsky A; Michalopoulos G; Viazis N; Fousekis FS; Psistakis A; Noviello D; Nascimento CND; Caron B; Kitsou V; Bamias G; García MJ; Zacharopoulou E; Foteinogiannopoulou K; D'Amico F; Koutroubakis I; Ellul P; Tzouvala M; Peyrin-Biroulet L; Torres J; Caprioli F; Karmiris K; Theodoropoulou A; Katsanos KH; Christodoulou DK; Mantzaris GJ; Kopylov U; Gisbert JP; Danese S; Magro F; Carla F; Fiorino G
    United European Gastroenterol J; 2024 Jun; 12(5):543-551. PubMed ID: 38419274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
    Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study.
    Singh A; Midha V; Kaur K; Mahajan R; Singh D; Kaur R; Kohli A; Chawla A; Sood K; Bansal N; Sood A
    J Crohns Colitis; 2024 Feb; 18(2):300-307. PubMed ID: 37656880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review.
    Irving PM; Hur P; Gautam R; Guo X; Vermeire S
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1026-1040. PubMed ID: 39213145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tofacitinib for the treatment of ulcerative colitis.
    Izzo R; Bevivino G; Monteleone G
    Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
    Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
    Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.